Cervical cancer screening among HIV-infected women in a health department setting

AIDS Patient Care and STDs

Volumn 24, Issue 8, 2010, Pages 471-475

  Logan, Jennifer L ^a   Khambaty, Maria Q ^a   D'Souza, Karina M ^a   Menezes, Lynette J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; ETHNICITY; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; UTERINE CERVIX CANCER;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; EARLY DETECTION OF CANCER; FEMALE; FLORIDA; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MIDDLE AGED; POVERTY; PUBLIC ASSISTANCE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 77955912776     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0295     Document Type: Article

References (32)

1. Ebrahim SH, Abdullah AS, McKenna M, Hamers FF. AIDSdefining cancers in Western Europe, 1994-2001. AIDS Patient Care STDs 2004;18:501-508.
2. Dhir AA, Sawant SP. Malignancies in HIV: The Indian scenario. Curr Opin Oncol 2008;20:517-521.
3. Chin KM, Sidhu JS, Janssen RS, Weber JT. Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstet Gynecol 1998;92:83-87.
4. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004;328:57-63.
5. Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ, Wright TC, Jr. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 1995;85(5 Pt 1):680-686.
6. Massad LS, Riester KA, Anastos KM, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999;21:33-41.
7. Holmes RS, Hawes SE, Toure P, et al. HIV infection as a risk factor for cervical cancer and cervical intraepithelial neoplasia in Senegal. Cancer Epidemiol Biomarkers Prev 2009; 18:2442-2446.
8. Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007;196:887-894.
9. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-1510.
10. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
11. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-819.
12. Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ 1999;160:185-191.
13. De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S, Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008;122:244-246.
14. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003;15: 382-388.
15. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR. A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex Transm Infect 2000;76:257-261.
16. Anderson JR, Paramsothy P, Heilig C, Jamieson DJ, Shah K, Duerr A. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006;42:562-568.
17. Branca M, Rossi E, Alderisio M, et al. Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. Cytopathology 2001;12:84-93.
18. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.MMWRRecomm Rep 2009;58:1-207; quiz CE201-204.
19. Stein MD, Cunningham WE, Nakazono T, et al. Screening for cervical cancer in HIV-infected women receiving care in the United States. J Acquir Immune Defic Syndr 2001;27 :463-466.
20. Oster AM, Sullivan PS, Blair JM. Prevalence of cervical cancer screening of HIV-infected women in the United States. J Acquir Immune Defic Syndr 2009;51:430-436.
21. Breen N, Wagener DK, Brown ML, Davis WW, Ballard- Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001;93:1704-1713.
22. Coughlin SS, King J, Richards TB, Ekwueme DU. Cervical cancer screening among women in metropolitan areas of the United States by individual-level and area-based measures of socioeconomic status, 2000 to 2002. Cancer Epidemiol Biomarkers Prev 2006;15:2154-2159.
23. Cunningham WE, Sohler NL, Tobias C, et al. Health services utilization for people with HIV infection: Comparison of a population targeted for outreach with the U.S. population in care. Med Care 2006;44:1038-1047.
24. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 2007;109(2 Pt 1):360-370.
25. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer 2004;101(5):1051-1057.
26. Kaplan JE, Parham DL, Soto-Torres L, et al. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. J Acquir Immune Defic Syndr 1999;21:228-235.
27. Sullivan PS, Denniston M, Mokotoff E, Buskin S, Broyles S, McNaghten AD. Quality of care for HIV infection provided by Ryan White Program-supported versus Non-Ryan White Program-supported facilities. PLoS ONE 2008;3:e3250.
28. Keiser O, Martinez de Tejada B, Wunder D, et al. Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2006;43:550-555.
29. Koethe JR, Moore RD, Wagner KR. Physician specialization and women's primary care services in an urban HIV clinic. AIDS Patient Care STDs 2008;22:373-380
30. Klevens RM, Fleming PL, Mays MA, Frey R. Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol 1996;88:269-273.
31. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: The importance of abuse, drug use, and race. Am J Public Health 2004;94:1147-1151.
32. Safety of and immune response to the Human Papillomavirus (HPV) vaccine in HIV-infected women. November 1, 2009. http://clinicaltrials.gov/ct2/show/ NCT00604175?term= hpv+vaccine+in+hiv+females&rank=1 (Last accessed May 22, 2010).